5 Questions on Melanoma

Charting the Evolution of TKIs and Finding the Next Breakthrough in CML

Anticipated data from the ESMO Congress 2025 may have implications for standards of care across prostate and bladder cancer groups.

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Jorge E. Cortes, MD

October 13th 2025

64Cu-SAR-bisPSMA PET Detects More Prostate Cancer Lesions vs SOC

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

SAR-bisPSMA is a targeted copper theranostic that can be used for either imaging or therapy, depending on which copper isotope is paired with it.

Optimizing Care for TILs, Cellular Therapy in Melanoma and Solid Tumors

The novel PET imaging agent detected significantly more PSMA-positive prostate cancer lesions vs SOC in patients with low PSA levels.

A panel of oncology pharmacists discusses the role of lifileucel in metastatic melanoma and other considerations for using cellular therapy in solid tumors.

Brooke Adams, PharmD, BCOP;Natalie Brumwell, PharmD, BCOP;Bryant A. Clemons, PharmD, BCOP

October 6th 2025

Neoadjuvant Radiotherapy Improves OS With Trade-Off in Rectal Cancer

A panel of oncology pharmacists discusses the role of lifileucel in metastatic melanoma and other considerations for using cellular therapy in solid tumors.

Pathological analysis showed that neoadjuvant radiotherapy was associated with the downstaging of locally advanced rectal cancer.

Ficerafusp Alfa/Pembrolizumab Receives FDA BTD in Front-Line HNSCC

Neoadjuvant radiotherapy prior to surgery was associated with a 3-year OS rate of 88.5% in patients with locally advanced rectal cancer.

The full indication excludes patients with human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma.

How Will ESMO 2025 Data Shape the Future of Genitourinary Cancer Care?

A median OS of 21.3 months was found in the phase 1/1b trial evaluating ficerafusp alfa plus pembrolizumab in those with metastatic and recurrent HNSCC.

Related Content

Russ Conroy

Charting the Evolution of TKIs and Finding the Next Breakthrough in CML

Anticipated data from the ESMO Congress 2025 may have implications for standards of care across prostate and bladder cancer groups.

Jorge E. Cortes, MD

October 13th 2025

64Cu-SAR-bisPSMA PET Detects More Prostate Cancer Lesions vs SOC

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Optimizing Care for TILs, Cellular Therapy in Melanoma and Solid Tumors

The novel PET imaging agent detected significantly more PSMA-positive prostate cancer lesions vs SOC in patients with low PSA levels.

Brooke Adams, PharmD, BCOP;Natalie Brumwell, PharmD, BCOP;Bryant A. Clemons, PharmD, BCOP

October 6th 2025

Neoadjuvant Radiotherapy Improves OS With Trade-Off in Rectal Cancer

A panel of oncology pharmacists discusses the role of lifileucel in metastatic melanoma and other considerations for using cellular therapy in solid tumors.

Ficerafusp Alfa/Pembrolizumab Receives FDA BTD in Front-Line HNSCC

Neoadjuvant radiotherapy prior to surgery was associated with a 3-year OS rate of 88.5% in patients with locally advanced rectal cancer.